Genesis Cancer Care Institute Treatment Trials - Genesis Health System

Cancer Clinical Trials

Clinical trials are research studies in which people help doctors find ways to improve health and cancer care. Each study tries to answer scientific questions and to find better ways to prevent, diagnose or treat cancer. Learn more about the different types and phases of clinical trials.

Why should I participate in a clinical trial?

Today it is possible to enroll in a clinical trial as the first step in your treatment after a cancer diagnosis. There are literally hundreds of trials available across the country. In fact, many of our most effective treatments used today for breast, colon, rectal and childhood cancers are the result of recent successes in clinical trials. As a participant a patient has the opportunity to help further the cause for other cancer patients, and possibly be helped by the treatments they receive. Participation in a clinical trial is voluntary. 

Below is a listing current treatment clinical trials for cancer offered through the Genesis Cancer Care Institute and Iowa Cancer Specialists.

Each trial below is linked to a complete description provided by the National Cancer Institute. If you need assistance with this process, contact us. 

You may search for other clinical trials through the following links: National Cancer Institute Clinical Trial Search; Emerging Med; Trial Check; or Center Watch.

Showing 1-10 of 15

Sorted By:

  • Breast Cancer: Alliance A011401

    This study is being done to see if losing weight may help prevent breast cancer from coming back (recurring).

  • Breast Cancer: Alliance A011502 (ABC Study)

    The purpose of this study is to compare any good and bad effects of using aspirin after someone has completed the usual chemotherapy, surgery and/or radiation therapy for breast cancer.

  • Breast Cancer: Breast Cancer Collaborative Registry

    This registry/tissue bank is focused on the collection of detailed information and biological samples on participants to help create a resource that will be helpful to researchers in future studies related to breast cancer.

  • Breast Cancer: EA1131

    The purpose of this study is to compare getting more treatment with capecitabine (i.e. one of the usual approaches), to any good and bad effects of getting more treatment with a platinum-based chemotherapy (cisplatin or carboplatin), after surgery for patients with triple-negative breast cancer.

  • Breast Cancer: NRG-BR003

    The purpose of this study is to compare the good and bad effects of the chemotherapy drug, carboplatin, given with the usual chemotherapy drugs after surgery, compared to the usual chemotherapy drugs given without carboplatin.

  • Breast Cancer: S1418/BR006

    The purpose of this study is to compare the usual approach (i.e. no more treatment or additional post-operative chemotherapy), to any effects, good and/or bad, of the experimental drug MK-3475 (also called pembrolizumab) after surgery.

  • Colon Cancer: A021502 (Adjuvant Treatment)

    This phase III trial studies combination chemotherapy and atezolizumab to see how well it works compared with combination chemotherapy alone in treating patients with stage III colon cancer and deficient deoxyribonucleic acid (DNA) mismatch repair.

  • Lung (Non-Small Cell) Cancer: A081105

    The purpose of this study is to compare any good and bad effects patients with early stage non-small cell lung cancer that was surgically removed may have when treated with the standard treatment against patients who are treated with the standard treatment plus erlotinib (an investigational drug).

  • Lung (Non-Small Cell) Cancer: A151216

    The purpose of this research study is to look at lung cancer patients’ tumors that were removed by surgery for certain genetic changes, and to possibly offer these patients a treatment study with drugs that may specifically target tumors that have these genetic changes.

  • Lung (Non-Small Cell) Cancer: E4512

    The purpose of this research study is to compare any good and bad effects of using the study drug, crizotinib (also known as XALKORI®), after completion of surgery and, in some cases, after chemotherapy and/or radiation therapy for patients with ALK-positive non-small cell lung cancer.

Contact Us

For more information about our cancer services, please contact:

563-421-1900

800-446-6088

or contact us online

Medical Oncologists

Cancer Navigators

Do you or a loved one have cancer? Let our Cancer Navigators guide the way. Call us today.

563-421-1900

Learn More

Give

When you join hands with your family, friends, and neighbors in their fight against cancer... you let them know they are not alone.

GIVE Today

Related Locations